// App-Quantinova.ai

943 : Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated

Researchers

Presenter

  • Hedwig Kasparu

Principal Investigators

  • Richard Greil

  • Zdenek Adam

  • Clemens Leitgeb

  • Ercan Muldur

  • Elisabeth Rauch

  • Niklas Zojer

  • Eva Maria Autzinger

  • Werner Linkesch

  • Thomas Kuhr

  • Ludek Pour

Medical Centers

  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

  • Department of Radiation Oncology, Medical University of Graz, Graz, Austria

  • Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria

  • Department III of Internal Medicine, University Hospital of Salzburg, Salzburg, Austria

  • st Department of Internal Medicine, Center for Oncology and Hematology, Wilhelminenhospital, , Austria

  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

  • Dpt. of Internal Medicine, Hospital Elisabethinen, Linz, Austria

Locations

  • Czech Republic

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Multiple Myeloma

  • Thrombocytopenia

  • Lymphomas

  • Anemia

Biomarkers

  • Circulating tumor cells

  • Purine nucleoside phosphorylase

  • Lactate dehydrogenase

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bendamustine

  • Lenalidomide

  • Bortezomib

Outcome

  • N/A

Study Design

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved